Latest available resultsQuarter ended March 31, 202610-Q · April 29, 2026
Filed with the SECBIOGEN INC.
BIIBPharma & biotech
Results announcedJuly 29, 2026▲ +19.8%
Detailed filing pendingNext reportOctober 28, 2026Analyst forecast 2.07 $/share
Revenue
$2.48B
▲ +1.9% vs prior year% YoY
Net income
$319.50M
▲ +32.8% vs prior year% YoY
EPS
2.15$
▲ +31.1% vs prior year% YoY
Net margin
12.9%
▲ +3.0 percentage points vs prior year pp YoY
Revenue▲ +1.9 %
Margins (% of revenue)GrossOperating N/ANet
Net income▲ +32.8 %
EPS▲ +31.1 %
View financial tableQuarter ended March 31, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $2.48B | |
| Gross profit | $1.82B | 73.3 % |
| Operating income | — | |
| Net income | $319.50M | 12.9 % |
| R&D | — | |
| EPS (diluted) | 2.15 $ | |
| Balance sheet | ||
| Assets | $29.48B | |
| Liabilities | $10.83B | |
| Equity | $18.65B | |
| Cash | — | |
| Capital | ||
| Shares outstanding | 147.64M | as of 2026-04-27 |
| Public float | — | |